---
schema_version: "secwatch.filing_event.v1"
accession: "0001494650-24-000027"
form_type: "8-K"
ticker: null
cik: "0001494650"
company_name: "OptiNose, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:29:18.815062+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptiNose amends debt covenants with BioPharma Credit, sets XHANCE sales targets through 2027

## Summary
- Minimum trailing 12-month XHANCE net sales/royalties set: $70M (Mar 31, 2024) rising to $160M (June 30, 2027).
- Make-whole premium on prepayments capped at $24M aggregate; formula changes based on prepayment timing relative to Nov 2024 and May 2026.
- All other terms of the A&R Note Purchase Agreement remain unchanged; no default exists as of amendment date.

## SEC filing metadata
- accession: 0001494650-24-000027
- form_type: 8-K
- cik: 0001494650
- company_name: OptiNose, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000027/0001494650-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000027/optn-20240308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001494650-24-000027
- JSON: https://secwatch.observer/filing/0001494650-24-000027.json
- Plain text: https://secwatch.observer/filing/0001494650-24-000027.txt

## Key facts
- Material Agreements
  OptiNose, Inc. amended Second Amendment with BioPharma Credit PLC (effective 2024-03-08).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: BioPharma Credit PLC
  - Effective: 2024-03-08
  source text: On March 8, 2024, OptiNose, Inc. (the “Company”) entered in a Second Amendment (the “Second Amendment”) to its Amended and Restated Note Purchase Agreement dated November 21, 2022, as amended on March 5, 2024, among the Company, OptiNose US, Inc., the purchaser parties defined therein and BioPharma Credit PLC (as amended, the “A&R Note Purchase Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000027/0001494650-24-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.